42 results
8-K/A
SLRN
Acelyrin Inc
28 May 24
Departure of Directors or Certain Officers
5:20pm
benefits, including the following: a lump sum payment equal to approximately 18 months of base salary, approximately 18 months of equity award … level, which provides Ms. Kim with the same severance benefits as previously provided to Dr. Lin under the Severance Plan, which benefits are described
DEFA14A
SLRN
Acelyrin Inc
9 May 24
Additional proxy soliciting materials
8:14am
pursuant to which the Company agreed to provide Dr. Lin with certain benefits, including the following: a lump sum payment equal to approximately 18 … to which the Company agreed to provide Mr. Oyston with certain benefits, including the following: 12 months of each of salary continuation, COBRA
8-K
EX-10.2
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
salary and benefits through and until the Termination Date (defined below).
WHEREAS, the Parties have mutually agreed to terminate the employment … of Employee’s execution of this Agreement, the Company will provide Employee with the following severance benefits:
a. Severance Payment. The Company
8-K
EX-99.1
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
protection; delays or failures to secure adequate supply of its product candidates; ACELYRIN’s failure to realize the expected benefits of its
8-K
d8ig4t6
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
8-K
EX-10.1
k9ppp triyn
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
DEF 14A
yuxk7m7smsg0wxczh
22 Apr 24
Definitive proxy
4:10pm
10-K
zqdvz s4kf2zz
28 Mar 24
Annual report
4:21pm
10-K
EX-4.3
ddo0038nuvw6obrjwhwd
28 Mar 24
Annual report
4:21pm
10-K
EX-97.1
zjke09jn1b4cf
28 Mar 24
Annual report
4:21pm
8-K
EX-99.1
igtaq5pv2yy5w 48ey
28 Mar 24
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
4:08pm
8-K
EX-99.2
dbnt2jvc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.3
rhf9b1luq33mr68
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.1
f9meq azbuqhi
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.1
ki1yl49ziyi48l qbl
27 Nov 23
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
4:31pm
8-K
EX-99
lyjkchmj3 ld6mus
7 Nov 23
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
4:23pm
8-K
br2ci3xc
21 Aug 23
Departure of Directors or Certain Officers
4:03pm
8-K
EX-99.1
xdb9udgk72id5k84rzb
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm